LGVN
No price yet
Announcements
Nothing here yet
Daily updates
- Longeveron's Phase 2b ELPIS II trial of laromestrocel in hypoplastic left heart syndrome failed to meet its primary RVEF endpoint, while secondary survival and MACE outcomes also lacked statistical significance.Sep 19, 2026
- Longeveron reported that the Phase 2b ELPIS II trial of laromestrocel missed its primary efficacy endpoint in HLHSSep 17, 2026
FDA designations
Nothing here yet
News
- Longeveron reported topline results from the Phase 2b ELPIS II trial evaluating laromestrocel as a potential treatment for hypoplastic left heart syndromeSep 17, 2026
- Longeveron published Phase 2b results in Cell Stem Cell showing stem cell therapy improved age-related frailtyFeb 26, 2026
- Longeveron received FDA Type C meeting grant ahead of ELPIS II Phase 2 HLHS trial readoutJan 27, 2026
- Longeveron licenses new cardiac-selective induced pluripotent stem cell technology for cardiovascular disease treatmentJul 22, 2025
- Longeveron receives FDA IND approval for Phase 2 pivotal study of Laromestrocel in pediatric dilated cardiomyopathyJul 9, 2025